Metraipolis › archive › dc_ed01a7fb76cb

Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial — Europe PMC PMID:41636590

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41636590
DOI
10.1093/jbmr/zjag013
License (as archived)
solo-consultazione
Archived
2026-10-07T12:19:05.785Z
SHA-256 of the archived text
8c8af49ee2e2a61ddb877bae5ac015fad6f2962e4f4d1abfd1daed00cb2d1ff5
Stable URL of this page
https://metraipolis.com/documento/dc_ed01a7fb76cb

How to cite

Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial — Europe PMC PMID:41636590 — Europe PMC (en), https://europepmc.org/article/MED/41636590 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ed01a7fb76cb (Metraipolis archive dc_ed01a7fb76cb, sha256 8c8af49ee2e2a61ddb877bae5ac015fad6f2962e4f4d1abfd1daed00cb2d1ff5)
BibTeX
@misc{dced01a7fb76cb,
  title = {Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial — Europe PMC PMID:41636590},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41636590},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ed01a7fb76cb; sha256 8c8af49ee2e2a61ddb877bae5ac015fad6f2962e4f4d1abfd1daed00cb2d1ff5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41636590. Agents can read the archived copy with the MCP tool read_document.